FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379331375> ?p ?o ?g. }

• W4379331375 endingPage "6049" @default.
• W4379331375 startingPage "6049" @default.
• W4379331375 abstract "6049 Background: Over 70% of NPC patients were local advanced NPC (LANPC). The 5-year local recurrence-free survival rate is only 70% in T3-4 patients. Neoadjuvant chemotherapy (NACT) followed with concurrent chemoradiotherapy (CCRT) was recommended for LANPC patients. Low-dose fractionated radiotherapy (LDFRT), which is < 100cGy, induces enhanced cell killing by the hyper-radiation sensitivity phenomenon and potentiates effects of chemotherapy. The synergy of LDFRT and NACT has not been used in the clinical practice and few studies focused on it. A single arm study found the ORR of primary site was improved to 90% for head and neck squamous carcinoma patients treated with LDFRT and NACT. Our previous study found the ORR of lymph nodes was higher in LDFRT group for high-risk LANPC patients. However, another study showed there was no significant difference between LDFRT and control group for LANPC patients. So, we aimed to investigate the potential efficacy of this novel neoadjuvant therapy for T3-4 NPC patients. Methods: 60 pathological confirmed T3-4 (UICC/AJCC8 th ) NPC patients were prospectively enrolled in our study. They were randomly assigned to two groups. For the LDFRT group, the patients received 3 cycles of NACT (docetaxel 75mg/m 2 D1, cisplatin 80mg/m 2 D1) with LDFRT, and followed with CCRT. LDFRT was delivered as 50cGy per fraction twice a day to primary site on D1,2 for each cycle of NACT. The patients in the control group only received NACT and followed with CCRT. All the patients underwent IGRT. RECIST criteria and CTCAE 5.0 was used to evaluate the ORR and toxicity at post-NACT and the completion of CCRT. Results: from Feb 2022 to Dec 2022, 60 T3-4 NPC patients were included, and 30 patients for each group. For the primary site, the median volume reduction rate and the ORR after NACT was significantly improved in LDFRT group (69.27% vs 40.10%, p< 0.001;93.33% vs 73.33%, p= 0.038). For the median volume reduction rate of primary site and lymph node, it was also obviously improved in LDFRT group (86.59% vs 55.43%, p< 0.001). Though there was a tendency of ORR improvement in LDFRT group, but no significant difference (96.67% vs 83.33%, p= 0.195). After the completion of CCRT, the median volume reduction rate of primary site had an increased tendency in LDFRT group (96.16% vs 88.3%, p= 0.065), but the ORR had no statistical significance (LDFRT group: CR 45.8%, PR 54.2%; control group: CR 37.5%, PR 62.5%). For the toxicity, the incidence of grade 3-4 adverse events had no difference between two groups ( p= 0.786). No grade 5 adverse events occurred. Conclusions: LDFRT combined with NACT could obviously improve the median volume reduction rate and ORR of primary tumor for T3-4 NPC patients, and the toxicity was similar and tolerable. The novel treatment could be a promising strategy to improve treatment response, and needed to be confirmed further. Clinical trial information: NCT05503914 ." @default.
• W4379331375 created "2023-06-05" @default.
• W4379331375 creator A5011626848 @default.
• W4379331375 creator A5030684731 @default.
• W4379331375 creator A5038562185 @default.
• W4379331375 creator A5042776688 @default.
• W4379331375 creator A5043019475 @default.
• W4379331375 creator A5045032755 @default.
• W4379331375 creator A5046521928 @default.
• W4379331375 creator A5051434566 @default.
• W4379331375 creator A5053311266 @default.
• W4379331375 creator A5059607192 @default.
• W4379331375 creator A5064826355 @default.
• W4379331375 creator A5066887020 @default.
• W4379331375 creator A5071949575 @default.
• W4379331375 creator A5079308651 @default.
• W4379331375 date "2023-06-01" @default.
• W4379331375 modified "2023-09-27" @default.
• W4379331375 title "Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial." @default.
• W4379331375 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.6049" @default.
• W4379331375 hasPublicationYear "2023" @default.
• W4379331375 type Work @default.
• W4379331375 citedByCount "0" @default.
• W4379331375 crossrefType "journal-article" @default.
• W4379331375 hasAuthorship W4379331375A5011626848 @default.
• W4379331375 hasAuthorship W4379331375A5030684731 @default.
• W4379331375 hasAuthorship W4379331375A5038562185 @default.
• W4379331375 hasAuthorship W4379331375A5042776688 @default.
• W4379331375 hasAuthorship W4379331375A5043019475 @default.
• W4379331375 hasAuthorship W4379331375A5045032755 @default.
• W4379331375 hasAuthorship W4379331375A5046521928 @default.
• W4379331375 hasAuthorship W4379331375A5051434566 @default.
• W4379331375 hasAuthorship W4379331375A5053311266 @default.
• W4379331375 hasAuthorship W4379331375A5059607192 @default.
• W4379331375 hasAuthorship W4379331375A5064826355 @default.
• W4379331375 hasAuthorship W4379331375A5066887020 @default.
• W4379331375 hasAuthorship W4379331375A5071949575 @default.
• W4379331375 hasAuthorship W4379331375A5079308651 @default.
• W4379331375 hasConcept C126322002 @default.
• W4379331375 hasConcept C141071460 @default.
• W4379331375 hasConcept C143998085 @default.
• W4379331375 hasConcept C168563851 @default.
• W4379331375 hasConcept C203092338 @default.
• W4379331375 hasConcept C2776611710 @default.
• W4379331375 hasConcept C2776694085 @default.
• W4379331375 hasConcept C2778424827 @default.
• W4379331375 hasConcept C2778997737 @default.
• W4379331375 hasConcept C2781190966 @default.
• W4379331375 hasConcept C509974204 @default.
• W4379331375 hasConcept C71924100 @default.
• W4379331375 hasConceptScore W4379331375C126322002 @default.
• W4379331375 hasConceptScore W4379331375C141071460 @default.
• W4379331375 hasConceptScore W4379331375C143998085 @default.
• W4379331375 hasConceptScore W4379331375C168563851 @default.
• W4379331375 hasConceptScore W4379331375C203092338 @default.
• W4379331375 hasConceptScore W4379331375C2776611710 @default.
• W4379331375 hasConceptScore W4379331375C2776694085 @default.
• W4379331375 hasConceptScore W4379331375C2778424827 @default.
• W4379331375 hasConceptScore W4379331375C2778997737 @default.
• W4379331375 hasConceptScore W4379331375C2781190966 @default.
• W4379331375 hasConceptScore W4379331375C509974204 @default.
• W4379331375 hasConceptScore W4379331375C71924100 @default.
• W4379331375 hasIssue "16_suppl" @default.
• W4379331375 hasLocation W43793313751 @default.
• W4379331375 hasOpenAccess W4379331375 @default.
• W4379331375 hasPrimaryLocation W43793313751 @default.
• W4379331375 hasRelatedWork W2392262560 @default.
• W4379331375 hasRelatedWork W2554758684 @default.
• W4379331375 hasRelatedWork W2742488328 @default.
• W4379331375 hasRelatedWork W2798231002 @default.
• W4379331375 hasRelatedWork W2995168058 @default.
• W4379331375 hasRelatedWork W3022553951 @default.
• W4379331375 hasRelatedWork W3094360059 @default.
• W4379331375 hasRelatedWork W3207536042 @default.
• W4379331375 hasRelatedWork W4377220531 @default.
• W4379331375 hasRelatedWork W4379283449 @default.
• W4379331375 hasVolume "41" @default.
• W4379331375 isParatext "false" @default.
• W4379331375 isRetracted "false" @default.
• W4379331375 workType "article" @default.